A ternary outcome for Tocagen
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
Second time lucky for Astra in lupus
The extensively overhauled Tulip-2 study of anifrolumab in lupus is an unexpected success.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Neptune leaves Astra at sea
The Neptune lung cancer study fails, denting yet further Astrazeneca and Bristol-Myers Squibb’s chances of challenging Merck & Co’s Keytruda on the basis of tumour…
Zepsyre has a path to market at last
Pharmamar says the US FDA has given an accelerated approval filing plan its blessing, and that means a regulatory submission this year.
Nektar’s call for calm backfires
In blaming bempegaldesleukin’s falling efficacy on poor manufacturing Nektar has alarmed investors even more.
Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst
A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.
A recap on the past few months of data digging and analysis
Using EvaluatePharma data Vantage explored investment trends in biopharma and medtech, sales per employee at big drug makers, and the declining number of late-stage…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.